Key result
Experimental human metapneumovirus vaccines and monoclonal antibodies show preclinical promise despite lacking licensed therapeutics.
This review highlights the current experimental approaches for HMPV immunization and therapy, noting the lack of licensed treatments.
No licensed HMPV vaccines or therapies exist; leaves open translation of animal-model promise to human trials.
Human metapneumovirus (HMPV) is a paramyxovirus discovered in 2001 in the Netherlands. Studies have identified HMPV as an important causative agent of acute respiratory disease in infants, the elderly, and immunocompromised individuals. Clinical signs of infection range from mild upper respiratory illness to more serious lower respiratory illness, including bronchiolitis and pneumonia. There are currently no licensed therapeutics or vaccines against HMPV. However, several research groups have tested vaccine candidates and monoclonal antibodies in various animal models. Several of these approaches have shown promise in animal models. This minireview summarizes the current therapies used to treat HMPV infection as well as different approaches for immunization.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2015) conducted a review in Human metapneumovirus (HMPV) infection. Vaccine candidates and monoclonal antibodies was evaluated. Vaccine candidates and monoclonal antibodies against human metapneumovirus have shown promise in various animal models, though no licensed therapeutics or vaccines currently exist.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: